[CLL] Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies
Arnon P. Kater, Sanne H. Tonino, Marie Jose Kersten et al.
Key Points:
PI3Kd involved in proliferation and survival of malignant B-cells and trafficking to lymphoid tissues.
8 subjects with CLL and 4 subjects with NHL enrolled, 9/12 remained on-study.
AEs related to drug: In 6 subjects grade 1 events of footpad neuropathy, diarrhea, edema ; grade 2 - hyperkalemia, worsening creatinine; grade 4 - neutropenia
Implications:
- GS-9820 in recurrent lymphoid malignancies demonstrates clinical activity; doses range from 50 mg to 400 mg BID.
View the original abstract on the ASH website.
